Redeye revises its financial forecast and valuation of Polygiene following the change of lead analyst. The key changes are related to the cost outlook, where we find an even greater scalability going forward. Based on our revised outlook with emphasis on stronger operational leverage, we raise medium and long-term margins, positively impacting our valuation range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/